TNFRSF9 and colorectal carcinoma: Meanwhile, the expression of CD137 and CD107a in CD8+ T and NK cells were improved by combined administration of IL‐33 and cetuximab (Figure 4D–E), which was also consistent with the data from cetuximab‐treated patients with CRC.